Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Coronaviruses, that are now well-known to the public, include a family of viruses that can
cause severe acute respiratory syndrome (SARS) and other respiratory diseases, such as …

Abstract As SARS-CoV-2 Omicron and other variants of concern (VOCs) continue spreading
worldwide, development of antibodies and vaccines to confer broad and protective activity is …

Antibodies binding to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
spike have therapeutic promise, but emerging variants show the potential for virus escape …

Severity of COVID-19 shows an extraordinary correlation with increasing age. We generated
a mouse model for severe COVID-19 and show that the age-dependent disease severity is …

Nanobodies offer several potential advantages over mAbs for the control of SARS-CoV-2.
Their ability to access cryptic epitopes conserved across SARS-CoV-2 variants of concern …

Respirovirus 3 is a leading cause of severe acute respiratory infections in vulnerable human
populations. Entry into host cells is facilitated by the attachment glycoprotein and the fusion …

The ongoing COVID‐19 pandemic and the emergence of new SARS‐CoV‐2 variants of
concern (VOCs) requires continued development of effective therapeutics. Recently, we …

SARS-CoV-2 and its variants have persisted in this ongoing COVID-19 pandemic. While the
vaccines have greatly reduced the COVID-19 cases, hospitalizations, and death, about half …

In the past two decades, the emergence of coronavirus diseases has been dire distress on
both continental and global fronts and has resulted in the search for potent treatment …